|
|
Corrigendum to ‘Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers’
G. Fossard
,
F. Broussais
,
I. Coelho
,
S. Bailly
,
E. Nicolas-Virelizier
et al.
Journal articles
hal-03440923v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Etude de phase II de l’association chemofree obinituzumab et idélalisib dans la maladie de Waldenström en rechute ou réfractaire : résultats de l’analyse intermédiaire, après la phase d’induction
C. Tomowiak
,
S. Chevret
,
S. Poulain
,
C. Herbaux
,
A. Perrot
et al.
40e Congrès de la Société Française d’Hématologie, Sep 2020, Paris, France. 26 (S4), pp.135, 2020, Hématologie
Conference poster
hal-02945874v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Front-line chemo-immunotherapy is not inferior to ibrutinib in CLL
M. van Gelder
,
O. Tournilhac
,
D. Te Raa
,
H.P.J. Visser
Journal articles
hal-03440402v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Prospective, Multicentric Phase II Randomized Trial Comparing the Efficacy of Methotrexate or Cyclophosphamide in Large Granular Lymphocytic Leukemia: A French National Study. Report on the Interim Analysis
T. Lamy
,
C. Pastoret
,
R. Houot
,
Loic Ysebaert
,
M. Hunault
et al.
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. 134 (Suppl 1), pp.1545, 2019, Blood
Conference poster
hal-02427556v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia
C. Kornauth
,
C. Herbaux
,
B. Boidol
,
C. Guillemette
,
P. Caron
et al.
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. 134 (Suppl 1), pp.3965, 2019, Blood
Conference poster
hal-02427551v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study
Laetitia Largeaud
,
Pascale Cornillet-Lefebvre
,
Jean-François Hamel
,
Pierre-Yves Dumas
,
Naïs Prade
et al.
Journal articles
hal-03441014v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Aggressive skin cancers in patients who experienced chronic GvHD after allogeneic bone marrow transplantation
A Zampaolo
,
J. Kanold
,
O. Tournilhac
,
F Franck
,
M Bachelerie
et al.
Journal articles
hal-01655888v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Evolution du taux de gammaglobulines chez les patients atteints de leucémie lymphoïde chronique traités par ibrutinib
A. Teste
,
C. Protin
,
L. Oberic
,
N. Diop
,
C. Croizier
et al.
40e Congrès de la Société Française d’Hématologie, Sep 2020, Paris, France. 26 (S4), pp.129, 2020, Hématologie
Conference poster
hal-02945852v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Open Label Non-Randomized Phase II Study Exploring «Chemo-Free » Treatment Association with Idelalisib + Obinutuzumab in Patients with Relapsed/Refractory (R/R) Waldenstrom's Macroglobulinemia (MW), a Filo Trial: Results of the Intermediary Analysis of the Induction Phase
C. Tomowiak
,
K. Desseaux
,
S. Poulain
,
C. Herbaux
,
A. Perrot
et al.
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. pp.346
Conference papers
hal-02418223v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Characterizing the Anti-Apoptotic Dependencies of T-Cell Prolymphocytic Leukemia Identifies HDAC and JAK/STAT Pathway Inhibitors As Promising Combination Partners to Augment Bcl-2 Targeted Killing By Venetoclax
C. Herbaux
,
C. Kornauth
,
S. Poulain
,
O. Tournilhac
,
M.C. Collins
et al.
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. pp.807
Conference papers
hal-02418469v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Maintenance of Long-Term Undetectable Minimal Residual Disease after Combination of Ibrutinib with Abbreviated Chemotherapy in the Icll-07 Filo Trial
A.S. Michallet
,
M.S. Dilhuydy
,
F. Subtil
,
V. Rouille
,
B. Mahe
et al.
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. 134 (Suppl 1), pp.3038, 2019, Blood
Conference poster
hal-02427562v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Évolution naturelle des cavernomes portaux non liés à une hépatopathie. Étude rétrospective monocentrique de 32 observations
A.S. Resseguier
,
M. André
,
E.A. Orian Lazar
,
G. Bommelaer
,
O. Tournilhac
et al.
La Revue de Médecine Interne, 2016, 37 (6), pp.394-398
Journal articles
hal-02013813v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Maintien à long terme d’une réponse complète avec maladie résiduelle indétectable après une stratégie de traitement combinant de l’ibrutinib à une immunochimiothérapie ≪ adaptée ≫ chez les patients atteints d’une leucémie lymphoïde chronique non antérieurement traitée
A.S. Michallet
,
M.S. Dilhuydy
,
F. Subtil
,
V. Rouille
,
B. Mahé
et al.
40e Congrès de la Société Française d’Hématologie, Sep 2020, Paris, France. 26 (S4), pp.125, 2020, Hématologie
Conference poster
hal-02945820v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study
Laetitia Largeaud
,
Pascale Cornillet-Lefebvre
,
Jean-François Hamel
,
Pierre-Yves Dumas
,
Naïs Prade
et al.
Journal articles
hal-03623649v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|